Vyroubalova Eva Cachin, Hartley Oliver, Mermod Nicolas, Fisch Igor
Institute of Biotechnology, University of Lausanne, 1005 Lausanne, Switzerland.
Mol Immunol. 2006 Apr;43(10):1573-8. doi: 10.1016/j.molimm.2005.09.025. Epub 2005 Nov 8.
The determination of protein-protein interactions and their role in diverse pathophysiological processes is a promising approach to the identification of molecules of therapeutic potential. This paper describes the identification of peptidic CCR5 receptor ligands as potential drug leads against HIV-1 infection using in vitro evolution based on phage display. A phage-displayed peptide library was used to select for anti-CCR5 peptide. Further in vitro evolution of the peptide by exon shuffling was performed to identify peptides with optimized characteristics for CCR5 receptor. This peptide inhibited HIV coreceptor activity in a cell fusion assay with an IC50 of 5 microM. It did not exhibit either agonistic or antagonistic activity on CCR5 in the concentration range used. To our knowledge, this is a first report that describes the identification of peptide ligands specific to the CCR5 receptor from a phage-displayed library and the maturation of the selected peptide sequence by gene shuffling.
确定蛋白质-蛋白质相互作用及其在多种病理生理过程中的作用是识别具有治疗潜力分子的一种有前景的方法。本文描述了基于噬菌体展示的体外进化技术鉴定肽类CCR5受体配体作为抗HIV-1感染潜在药物先导物的过程。利用噬菌体展示肽库筛选抗CCR5肽。通过外显子改组对该肽进行进一步体外进化,以鉴定具有优化CCR5受体特性的肽。在细胞融合试验中,该肽抑制HIV共受体活性,IC50为5 microM。在所使用的浓度范围内,它对CCR5既不表现出激动活性也不表现出拮抗活性。据我们所知,这是第一份描述从噬菌体展示文库中鉴定CCR5受体特异性肽配体以及通过基因改组使所选肽序列成熟的报告。